1569. Seroprevalence of Chlamydia trachomatis (CT) in Inner City Children and Adolescents - Implications for Vaccine Development
Session: Poster Abstract Session: Clinical Infectious Diseases: Sexually Transmitted Infections
Saturday, October 10, 2015
Room: Poster Hall
Background: CT remains the most prevalent sexually transmitted infection in developed and developing countries.Prevention of infection is an ideal application for a vaccine program. Similar to the HPV vaccine, the timing of immunization for a future CT vaccine should optimally precede sexual debut. However, there are limited epidemiologic studies of CT infection in an unselected pediatric and adolescent population since universal screening and treatment of pregnant women was implemented in the U.S. in 1993.

Methods: Anonymized serum samples were obtained from children in 2 hospitals in Brooklyn, NY from 2013-2015.  CT IgG was determined using EIA. The following age strata were used for the final analysis: 9-10, 11-12, 13-14, 15-16, 17-18, 19-20 y.

Results: 566 sera were included in the final analysis. Mean age was 16.6 y.  There were 214 (37.8%) males and 352 (62.2%) females. CT antibody was first detected at 18 y and 14 y for males and females, respectively. Prevalence by age stratum and sex are listed in Table 1. There were significant effects of age and gender on CT serological status (= 0.01; = 0.029, respectively).

Table 1.

Age Strata (y)


CT +/total 


95% CI

Males CT+/total


95% CI



0%, 0%


0%, 0%



0%, 0%


0%, 0%


1/39 (2.6%)

0%, 7.59%


0%, 0%


3/57 (5.3%)

0%, 11.12%


0%, 0%


15/88 (17%)

9.15%, 24.85%

3/47 (6.4%)

0%, 13.4%


20/128 (16%)

9.65%, 22.35%

7/76 (9.2%)

2.7%, 15.7%

Conclusion: The prevalence of antibody was higher in girls than their male counterparts, mirroring national surveillance trends based on NAATs. Antibody was first detected in females at 14 y and males at 18 y. The delay in male antibody detection may be due to later exposure and/or anatomical and physiological factors between the sexes. These data are critical in informing potential CT vaccine strategies. Future studies using a larger sample size and other populations will allow more precise estimates of age and gender-specific prevalence.

Natalie Banniettis, MD1, Sirisha Thumbu, MD2, Aviva Szigeti, MD1, Kobkul Chotikanatis, M.D.1, Marc Braunstein, MD1, Ghussai Abd El Gadir, MBBS3, Margaret Hammerschlag, MD, FIDSA1 and Stephan Kohlhoff, MD3, (1)Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY, (2)Family Medicine, Lutheran Medical Center, Brooklyn, NY, (3)Pediatric Infectious Disease, SUNY Downstate Medical Center, Brooklyn, NY


N. Banniettis, None

S. Thumbu, None

A. Szigeti, None

K. Chotikanatis, None

M. Braunstein, None

G. Abd El Gadir, None

M. Hammerschlag, None

S. Kohlhoff, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.